Susan Dexter

SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ.

SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ.

Xcellerex, Inc. manufactures and provides equipment to produce bio-molecules. Its products and services include FlexFactory, a bioprocess manufacturing platform that handles the production of bio-products, such as vaccines, yeast and insulins. The company was founded by Parrish M. Galliher in 2002 and was headquartered in Marlborough, MA.

Virica Biotech, Inc. is a Canadian company that specializes in viral medicines, including gene therapies, vaccines, and oncolytic viruses. The company is based in Ottawa, Canada and was founded in 2018 by Ella Korets-Smith and Jean-Simon Diallo. The company has developed a new product category of viral sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. The company's purpose is to realize the promise of viral medicines and extend the horizons of human healthcare. Jean-Simon Diallo has been the CEO since 2018.

SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ.

Virica Biotech, Inc. is a Canadian company that specializes in viral medicines, including gene therapies, vaccines, and oncolytic viruses. The company is based in Ottawa, Canada and was founded in 2018 by Ella Korets-Smith and Jean-Simon Diallo. The company has developed a new product category of viral sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. The company's purpose is to realize the promise of viral medicines and extend the horizons of human healthcare. Jean-Simon Diallo has been the CEO since 2018.

Virica Biotech, Inc. is a Canadian company that specializes in viral medicines, including gene therapies, vaccines, and oncolytic viruses. The company is based in Ottawa, Canada and was founded in 2018 by Ella Korets-Smith and Jean-Simon Diallo. The company has developed a new product category of viral sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. The company's purpose is to realize the promise of viral medicines and extend the horizons of human healthcare. Jean-Simon Diallo has been the CEO since 2018.

Virica Biotech, Inc. is a Canadian company that specializes in viral medicines, including gene therapies, vaccines, and oncolytic viruses. The company is based in Ottawa, Canada and was founded in 2018 by Ella Korets-Smith and Jean-Simon Diallo. The company has developed a new product category of viral sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. The company's purpose is to realize the promise of viral medicines and extend the horizons of human healthcare. Jean-Simon Diallo has been the CEO since 2018.

Virica Biotech, Inc. is a Canadian company that specializes in viral medicines, including gene therapies, vaccines, and oncolytic viruses. The company is based in Ottawa, Canada and was founded in 2018 by Ella Korets-Smith and Jean-Simon Diallo. The company has developed a new product category of viral sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. The company's purpose is to realize the promise of viral medicines and extend the horizons of human healthcare. Jean-Simon Diallo has been the CEO since 2018.

Virica Biotech, Inc. is a Canadian company that specializes in viral medicines, including gene therapies, vaccines, and oncolytic viruses. The company is based in Ottawa, Canada and was founded in 2018 by Ella Korets-Smith and Jean-Simon Diallo. The company has developed a new product category of viral sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. The company's purpose is to realize the promise of viral medicines and extend the horizons of human healthcare. Jean-Simon Diallo has been the CEO since 2018.